In a cross-sectional study of middle aged hypertensives, those with obstructive sleep apnoea syndrome (OSAS) compared with those without OSAS, demonstrated increased levels of high-sensitivity C-reactive protein (hs-CRP), interleukin 6 (IL-6), interleukin 18 (IL-18), tumour necrosis factor alpha (TNF-a) and asymmetric dimethyl-arginine (ADMA), at the same level of ambulatory pulsatile load and body size. Association of apnoea severity indices with the above-mentioned markers supports the incremental effect of OSAS on the cardiovascular risk duet of sub-clinical inflammation and endothelial dysfunction in the setting of hypertension.
Epidemiological evidence linking OSAS and hypertension is documented independently of confounding atherosclerotic factors and cardiovascular comorbidities. 1 However, many studies designed to identify the involved pathogenetic mechanisms mainly suffer from inadequate control for confounders such as body mass index and blood pressure (BP).
2 Diverse cytokines promote a wide range of atherogenic effects in various domains of the vasculature 3 reflecting alternative pathways of inflammatory activation. Furthermore, ADMA has been characterized as the 'uber marker' of endothelial dysfunction in multiple clinical settings including hypertension. 4 Repetitive upper airway collapses in OSAS result in hypoxia, hypercapnia and changes in intrathoracic pressure accompanied by a variety of autonomic, haemodynamic, humoral and cellular responses. We investigated the possible associations of OSAS with hs-CRP, IL-6, IL-18, TNF-a and ADMA in hypertensives.
The study population consisted of 73 consecutive non-diabetic patients with newly diagnosed (o2 years) untreated hypertension who were referred to our outpatient hypertensive clinic and presented high clinical evidence of OSAS. Diagnosis of hypertension was based on three outpatient measures of BP4140/90 mm Hg and confirmed by daytime ambulatory BP4135/85 mm Hg. Patients underwent the usual clinical and laboratory workup to rule out secondary hypertension.
Seventy-three newly diagnosed medication-naive hypertensives, without clinical evidence of OSAS matched for age, sex, smoking status, body mass index and ambulatory pulse pressure, were considered as controls. None of the participants had any history or clinical/laboratory evidence of recent infection, inflammation, or underwent any medical treatment (including lipid-lowering and hormone replacement therapy) 1 month prior to entry in the study. The study protocol was approved by our Institutional Ethics Committee and all participants gave written informed consent.
Venous blood samples were obtained from each participant after overnight fasting just after polysomnography for the determination of the metabolic profile, hs-CRP, IL-6, IL-18, TNF-a and ADMA. Based on polysomnography, apnoea/hypopnea index (AHI) was defined according to American Academy of Sleep Medicine Task Force clinical research criteria as the number of apnoea plus hypopnea episodes per hour of sleep. The lowest AHI class (o5) was defined as normal. The lower oxygen saturation value (minSatO 2 ) during sleep was also recorded.
All continuous variables are presented as means and standard deviations if their distribution was normal. On account of their skewed distribution the not normally distributed variables were logarithmically (log 10 ) transformed prior to statistical testing. Covariance analysis was performed to detect significant differences of inflammatory markers and ADMA between the groups after adjustment for covariates.
Our final hypertensive OSAS group comprised of 62 patients with AHI class X5 (of 73 with high clinical evidence of OSAS-11 patients had negative polysomnography) and our final group with hypertension alone comprised of 70 patients with negative polysomnography (of 73 patients without clinical evidence of OSAS-two patients were nonsleepy snorers and one patient was excluded because of positive polysomnography).
Hypertensives with OSAS compared with those without OSAS demonstrated increased levels of log 10 (hs-CRP) by 0.16 ± 0.2 mg l À1 , log 10 (IL-6) by 0.51 ± 0.3 pg ml À1 , log 10 (IL-18) by 0.1 ± 0.1 pg ml À1 , log 10 (TNF-a) by 0.23±0.2 pg ml À1 and log 10 (ADMA) by 0.06 ± 0.08 mmol l À1 (Po0.0001 for all) ( Table 1 ). Covariance analysis revealed that the above-mentioned differences remained significant even after adjustment for age, sex, body mass index and 24 h systolic and diastolic BP (Po0.0001 for all). In the entire population log 10 (AHI) and minSatO 2 were respectively correlated with log 10 (hs-CRP), log 10 (IL-6), log 10 (IL-18), log 10 (TNF-a) and log 10 (ADMA) (r ¼ 0.27 and r ¼ À0.31, r ¼ 0.58 and r ¼ À0.46, r ¼ 0.36 and r ¼ À0.33, r ¼ 0.37 and r ¼ À0.38 and r ¼ 0.41 and r ¼ À0.38, respectively, Po0.0001 for all). In addition, 24 h pulse pressure was correlated with log 10 (hs-CRP) (r ¼ 0.24, P ¼ 0.009), log 10 (IL-6) (r ¼ 0.18, P ¼ 0.034), log 10 (IL-18) (r ¼ 0.22, P ¼ 0.014), log 10 (TNF-a) (r ¼ 0.26, P ¼ 0.01) and log 10 (ADMA) (r ¼ 0.30, P ¼ 0.009) respectively. Finally, left ventricle mass index was correlated with all of the studied serological markers (Po0.01 for all).
The main finding of the study is that the presence of OSAS in hypertensives is accompanied by increased levels of sub-clinical inflammation markers and ADMA at the same level of body size and ambulatory pulsatile load. Moreover, the severity of OSAS is closely related to these markers suggesting that the syndrome promotes vascular damage in a 'dose-related' manner further increasing the cardiovascular risk in hypertension. To the best of our knowledge, this is the first study where the OSAS and the non-OSAS groups were initially matched for body mass index and ambulatory pulse pressure to limit their confounding impact on both inflammation and endothelial function.
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The observed association of ambulatory pulse pressure with all the studied serological markers confirms the notion that the imposition of oscillatory and low-shear stress on the vascular beds may activate inflammatory pathways and endothelial dysfunction. However, it is not clear whether the higher BP levels promote a cascade of pro-atherogenetic mechanisms or whether it is the other way around or even a bi-directional interrelationship. Notwithstanding, the repetitive paroxysmal effects of OSAS may exert an additive reinforcement of the pro-inflammatory atherogenic milieu beyond that attributed to both the increased 24 h diastolic BP and the night-time differential BP. 8, 9 Previous studies reported an impaired endothelium-dependent vasodilatation in OSAS patients with various comorbidities. 2 Along the same lines, ADMA was decreased after continuous positive airway pressure therapy. 10, 11 Our findings extended the above by showing that ADMA levels are interrelated with AHI and oxygen desaturation dipping, suggesting a progressive increase of the former marker along with OSAS severity.
Metabolic parameters did not differ in our setting, in contrast with previous studies. 2 This can be explained, partially at least, by the matching for confirmed by our findings, may represent either an epiphenomenon or a further confounder of the serological outcomes. From a clinical point of view, the higher level of inflammatory cytokines and ADMA in hypertensives with OSAS underscores the importance of the syndrome as an accelerator of the atherosclerotic process in an already vulnerable vascular substrate. Treatment of OSAS with continuous positive airway pressure may be effective in blunting atherosclerotic progression in hypertensives in an early phase, independent of BP lowering.
The cross-sectional nature of the study and the absence of an interventional arm (that is, continuous positive airway pressure) limit our ability to conclude any casual relationship between OSAS, subclinical inflammation and endothelial dysfunction. In Additional, possible circadian variations in the release of the studied markers could not be excluded. Finally, although our participants seem not to have the peripheral component of insulin resistance, the central one could not be ruled out.
In conclusion, hypertensive patients with OSAS compared with those without OSAS are characterized by increased levels of hs-CRP, IL-6, IL-18, TNF-a and ADMA at the same level of ambulatory pulsatile load and body size. 
